XORTX Therapeutics
XRTX
6 hedge funds and large institutions have $124K invested in XORTX Therapeutics in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
52% more capital invested
Capital invested by funds: $81.5K → $124K (+$42.1K)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more funds holding
Funds holding: 5 → 6 (+1)
0.28% more ownership
Funds ownership: 0.39% → 0.66% (+0.28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$128K |
| 2 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$12.4K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$8.35K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.47K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$773 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$69.9K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$11.2K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DS
1
DRW Securities
Chicago,
Illinois
| $109K | +$128K | +38,720 | New |
|
|
TSS
2
Two Sigma Securities
New York
| $7.08K | +$8.35K | +2,519 | New |
|
|
BBA
3
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| $4.74K | +$12.4K | +3,746 | New |
|
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$2.47K | +746 | +1,036% |
|
|
5
UBS Group
Zurich,
Switzerland
| $787 | +$773 | +233 | +496% |
|
|
CA
6
Clearstead Advisors
Cleveland,
Ohio
| $156 | – | – | – |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$69.9K | -17,265 | Closed |
|
|
XT
8
XTX Topco
George Town,
Cayman Islands
| – | -$11.2K | -2,764 | Closed |
|
|
SS
9
SBI Securities
Tokyo,
Japan
| – | -$1 | – | – |
|
XRTX Hedge Fund Activity: Q4 2025 in Review
6 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q4 2025, worth a combined $124K — up 52% from $81.5K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new XRTX positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $128K. The largest seller was Citadel Advisors, exiting entirely with an estimated $69.9K sold.
- 6 institutional investors held XORTX Therapeutics (XRTX) as of Q4 2025, up from 5 in Q3 2025.
- Funds reported $124K of XORTX Therapeutics stock for Q4 2025, up 52% quarter-over-quarter.
- 3 funds opened new XORTX Therapeutics positions in Q4 2025 and 2 closed out, a net change of +1 holder.
- The largest XORTX Therapeutics buyer in Q4 2025 was DRW Securities, an estimated $128K added.
- The largest XORTX Therapeutics seller in Q4 2025 was Citadel Advisors, an estimated $69.9K sold.
Based on aggregated 13F filings for Q4 2025.